Introduction {#S0001}
============

Circulating tumor cell (CTC) enumeration is gaining importance in cancer therapy due to its potential to guide prognosis and treatment, measure tumor burden and response to treatment, and detect recurrent disease.[@CIT0001] The prognostic value of CTCs has been established in studies of patients with both early-stage and metastatic breast cancer (MBC).[@CIT0002],[@CIT0003]

CELLSEARCH technology (Menarini Silicon Biosystems, Huntingdon Valley, PA, USA) has been cleared by the US Food and Drug Administration as an aid in monitoring patients with MBC, colorectal cancer, or prostate cancer.[@CIT0004] Prospective studies using CELLSEARCH have demonstrated that patients with MBC and ≥5 CTCs/7.5 mL of blood at baseline have shorter progression-free survival (PFS) and overall survival (OS) than those with \<5 CTCs. Moreover, CTC clearance during treatment (a decrease from ≥5 CTCs at baseline to \<5 CTCs postbaseline) has been associated with improved outcomes compared with no clearance (≥5 CTCs at all time points, including baseline).[@CIT0005],[@CIT0006] These findings have been confirmed by prospective and pooled analyses with larger patient numbers.[@CIT0007]--[@CIT0009]

A recent prospective CTC study included a subset of patients with hormone receptor-negative, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (triple-negative breast cancer \[TNBC\]). In that study, it was reported that OS outcomes were best in patients with low CTCs at baseline (\<5 CTCs/7.5 mL), followed by those who experienced a reduction in CTCs upon treatment (a decrease to \<5 CTCs from baseline). OS outcomes were worst among patients with CTCs unresponsive to therapy (persistent increase of ≥5 CTCs postbaseline).[@CIT0010]

The multicenter, open-label, randomized, Phase II/III tnAcity trial evaluated the efficacy and safety of 3 chemotherapy regimens (*nab*-paclitaxel \[nab-P\]/carboplatin \[C\], *nab*-P/gemcitabine \[G\], and G/C) as first-line treatment for patients with metastatic TNBC (mTNBC).[@CIT0011] *nab*-P/C treatment resulted in a significantly longer median PFS and numerically higher overall response rate (ORR) compared with *nab*-P/G or G/C; grade ≥3 adverse events were mainly hematologic.[@CIT0012] The findings of a prespecified exploratory analysis investigating the correlation of CTC levels with ORR, PFS, and OS are reported here.

Materials and Methods {#S0002}
=====================

Study Design and Patients {#S0002-S2001}
-------------------------

The tnAcity trial investigated weekly treatment with *nab*-P/C or *nab*-P/G vs G/C in patients with mTNBC ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul}), and the study design has been previously reported.[@CIT0012] Briefly, key eligibility requirements included measurable metastatic disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1, and prior adjuvant or neoadjuvant anthracycline therapy (unless not indicated by physician).

The trial was registered at ClinicalTrials.gov (NCT01881230), approved by institutional review boards or independent ethics committees at each of the 52 participating sites ([[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul}), and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Conference on Harmonisation. All patients provided written informed consent prior to study entry.

Endpoints and Study Assessments {#S0002-S2002}
-------------------------------

The primary endpoint of Phase II was investigator-assessed PFS per RECIST 1.1. Secondary endpoints included investigator-assessed ORR, OS, and safety. CTC enumeration was a prespecified exploratory endpoint. CTCs were measured before treatment on day 1 of cycle 1 (baseline) and day 1 of cycles 3 and 5 (postbaseline). Briefly, 8 to 10 mL of whole blood was collected in a CellSave blood collection tube (Menarini Silicon Biosystems). CTC enrichment and enumeration were performed using the CELLSEARCH CTC Test according to the manufacturer's instructions.

The standard, established CTC cutoff in the MBC setting is 5 CTCs.[@CIT0004],[@CIT0005] A cutoff of ≥1 CTC was used for the main analysis of the current study because it increased the sensitivity of the analysis. Cutoffs of ≥2 and ≥5 CTCs were used for supportive analyses. All CTC cutoffs and values are reported per 7.5 mL of blood. For analyses by CTC clearance, patients were classified into 3 groups according to presence of CTCs at baseline and change in CTC levels postbaseline: Group 1 (+ + +; CTCs elevated at baseline and both postbaseline visits), Group 2 (+ ± ±; CTCs elevated at baseline and cleared at ≥1 postbaseline visit), and Group 3 (−; no CTCs at baseline) ([[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul}). In additional analyses, patients were grouped exclusively by the presence or absence of CTCs at baseline.

Statistical Methods {#S0002-S2003}
-------------------

The Kaplan--Meier method was used to estimate the distribution of PFS and OS with a log-rank test. The Kaplan--Meier curves were presented individually for each group. The hazard ratio (HR) between these groups and the associated 2-sided 95% CI were estimated using a Cox proportional hazards model.

Results {#S0003}
=======

Patients and Baseline CTC Levels {#S0003-S2001}
--------------------------------

A total of 191 patients were enrolled in the tnAcity trial,[@CIT0012] and 126 patients were included in the main analysis (≥1-CTC cutoff; 24, 54, and 48 patients were included in Groups 1, 2, and 3, respectively). Across the 3 groups, most patients were aged \<65 years and had an ECOG PS of 0 ([Table 1](#T0001){ref-type="table"}). In the ≥2-CTC cutoff analysis, 16, 44, and 69 patients were included in Groups 1, 2, and 3, respectively, while the ≥5-CTC cutoff analysis included 10, 34, and 87 patients, respectively ([[Tables S3](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul} and [[S4](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul}).Table 1Patient Baseline Characteristics in the Main Analysis of ≥1 Circulating Tumor CellCharacteristicGroup 1 (+ + +) n = 24Group 2 (+ ± ±) n = 54Group 3 (−) n = 48Age, median (range), years57.0 (27--71)56.0 (27--74)56.5 (31--82) \<65, n (%)15 (62.5)42 (77.8)32 (66.7) ≥65, n (%)9 (37.5)12 (22.2)16 (33.3)Baseline ECOG PS, n (%) 015 (62.5)30 (55.6)31 (64.6) 19 (37.5)24 (44.4)16 (33.3) 2001 (2.1)Race, n (%) White18 (75.0)49 (90.7)37 (77.1) Black/African American4 (16.7)3 (5.6)7 (14.6) Not collected or reported2 (8.3)2 (3.7)4 (8.3)Region, n (%) North America13 (54.2)33 (61.1)23 (47.9) Western Europe11 (45.8)20 (37.0)25 (52.1) Australia01 (1.9)0Disease-free interval, n (%) ≤1 year7 (29.2)12 (22.2)14 (29.2) \>1 year17 (70.8)41 (75.9)34 (70.8)Triple negative at primary diagnosis, n (%)17 (70.8)45 (83.3)35 (72.9)Site of metastasis, n (%) Bone12 (50.0)21 (38.9)13 (27.1) Breast7 (29.2)18 (33.3)7 (14.6) Liver9 (37.5)17 (31.5)10 (20.8) Lung/thoracic11 (45.8)33 (61.1)35 (72.9) Lymph node(s)18 (75.0)45 (83.3)28 (58.3) Skin/soft tissue5 (20.8)10 (18.5)8 (16.7) Other4 (16.7)9 (16.7)10 (20.8) Abdomen/peritoneal2 (8.3)2 (3.7)0Prior taxane treatment, n (%)17 (70.8)29 (53.7)33 (68.8)[^1]

At baseline, the median CTC level in Group 1 was 21.5, with levels of 3.0 and 9.8 at cycles 3 and 5, respectively ([Table 2](#T0002){ref-type="table"}). In Group 2, patients had a median of 5.0 CTCs at baseline, and 0 CTCs were detected at cycles 3 and 5. Patients in Group 3 had no CTCs detected at baseline.Table 2Median Circulating Tumor Cell Values at Each AssessmentAssessment, Median (Range), CTCs/7.5 mL BloodGroup 1 (+ + +)Group 2 (+ ± ±)Group 3 (−)Baselinen = 24n = 54n = 4821.5 (0.5--478.5)5.0 (0.5--1211.5)0Cycle 3n = 18n = 52n = 463.0 (0.5--169.0)0 (0--3.0)0 (0--19.0)Cycle 5n = 14n = 50n = 249.8 (0.5--1380.0)0 (0--17.5)0 (0--3.0)[^2]

Efficacy {#S0003-S2002}
--------

Patients in Group 2 had the highest ORR (79.6%), followed by Group 3 (43.8%) and Group 1 (29.2%) ([Table 3](#T0003){ref-type="table"}). Patients in Group 2 also had a longer median PFS compared with Group 1 (8.5 vs 4.7 months; HR, 0.30 \[95% CI, 0.17--0.54\]; [Figure 1A](#F0001){ref-type="fig"}). The median PFS was 5.9 months in Group 3. Compared with Group 1 (9.8 months), the median OS was longer in both Groups 2 (17.8 months; HR, 0.35 \[95% CI, 0.20--0.62\]) and 3 (16.0 months; HR, 0.40 \[95% CI, 0.22--0.73\]; [Figure 1B](#F0001){ref-type="fig"}).Table 3Response by Change in Circulating Tumor Cell (CTC) Levels from Baseline in the Main Analysis of ≥1 CTCResponse, n (%)Group 1 (+ + +) n = 24Group 2 (+ ± ±) n = 54Group 3 (−) n = 48Overall response rate7 (29.1)43 (79.6)21 (43.8)Complete response1 (4.2)9 (16.7)3 (6.3)Partial response6 (25.0)34 (63.0)18 (37.5) Figure 1Efficacy outcomes by change in circulating tumor cell levels from baseline. Kaplan--Meier plots of (**A**) PFS and (**B**) OS.**Notes:** Group 1 (+ + +), elevated at baseline and elevated postbaseline; Group 2 (+ ± ±), elevated at baseline and cleared postbaseline (cycle 3 and/or cycle 5); Group 3 (−), no CTCs detected at baseline. ^a^ vs Group 1.**Abbreviations:** HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

The ORR and PFS results were supported by the ≥2- and ≥5-CTC cutoff analyses ([[Table S5](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul}). In the ≥2-CTC cutoff analysis, patients in Group 2 had a higher ORR (77.3%) compared with Group 3 (47.8%) and Group 1 (31.3%). In the same analysis, the median PFS was 8.9 months in Group 2 and 6.0 months in Group 3 vs 4.7 months in Group 1, and the median OS was 16.8 months in Group 2 and 16.2 months in Group 3 vs 9.8 months in Group 1. Similarly, in the ≥5-CTC cutoff analysis, the ORRs were 82.4%, 48.3%, and 20.0% in Groups 2, 3, and 1, respectively. The median PFS rates were 8.4, 6.5, and 4.7 months, respectively. Patients in Group 3 had the longest median OS (16.0 months), followed by Group 2 (15.4 months) and Group 1 (9.8 months) ([[Table S5](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul}).

Efficacy by Baseline CTC Levels {#S0003-S2003}
-------------------------------

An efficacy analysis based on the presence or absence of CTCs at baseline revealed that patients with 0 detected CTCs at baseline had a lower ORR (43.8%) than those with ≥1 CTC at baseline (64.1%). The median PFS (5.9 vs 7.0 months; HR, 1.45 \[95% CI, 0.93--2.25\]; [Figure 2A](#F0002){ref-type="fig"}) and OS (16.0 vs 15.0 months; HR, 0.90 \[95% CI, 0.57--1.42\]; [Figure 2B](#F0002){ref-type="fig"}) were similar for patients with 0 vs ≥1 CTC at baseline, respectively. Additional analyses using cutoffs of ≥2 and ≥5 CTCs at baseline support these results ([[Table S6](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul}).Figure 2Efficacy outcomes by the absence or presence of circulating tumor cells at baseline. Kaplan--Meier plots of (**A**) PFS and (**B**) OS.**Abbreviations:** CTC, circulating tumor cell; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

Efficacy by Treatment Group {#S0003-S2004}
---------------------------

An analysis of CTC dynamics by treatment received showed that more patients in the *nab*-P/C arm had postbaseline CTC clearance (Group 2) than in the *nab*-P/G and G/C arms (60.0% vs 28.2% vs 38.1%; [Table 4](#T0004){ref-type="table"}). In general, patterns of PFS were similar regardless of treatment arm, with numerically longer median PFS values associated with Groups 2 and 3 compared with Group 1; however, no formal statistical analyses were performed to support this comparison. These results were supported in the ≥2- and ≥5-CTC cutoff analyses ([[Table S7](https://www.dovepress.com/get_supplementary_file.php?f=208712.docx)]{.ul}).Table 4PFS by Treatment Arm and Change in Circulating Tumor Cell (CTC) Levels from Baseline in the Main Analysis of ≥1 CTCTreatmentCTC Groupn (%)Median PFS, Months*nab*-P/CGroup 1 (+ + +)4 (8.9)NEGroup 2 (+ ± ±)27 (60.0)8.94Group 3 (−)14 (31.1)4.37*nab*-P/GGroup 1 (+ + +)11 (28.2)4.24Group 2 (+ ± ±)11 (28.2)7.92Group 3 (−)17 (43.6)8.75G/CGroup 1 (+ + +)9 (21.4)3.52Group 2 (+ ± ±)16 (38.1)8.52Group 3 (−)17 (40.5)5.65[^3]

Discussion {#S0004}
==========

The tnAcity CTC analysis revealed better efficacy outcomes in patients with CTC clearance. A numerically higher percentage of patients in the *nab*-P/C arm experienced CTC clearance during treatment than in the *nab*-P/G and G/C arms, suggesting improved antitumor activity with *nab*-P/C. We report the results with ≥1-, ≥2-, and ≥5-CTC cutoffs, but to increase the sensitivity of our detection method, a cutoff of ≥1 CTC was used for the main analysis. Among the 3 cutoffs, the ≥1-CTC cutoff analysis included the largest number of patients (n = 24) in Group 1. As the CTC threshold increased, fewer patients were included in Group 1; therefore, these analyses were considered more cautiously. It should be noted that results were generally consistent across CTC thresholds.

The ORR was lower among patients with no detectable CTCs at baseline compared with those with ≥1 detectable CTC. Although the differences in PFS and OS between these cohorts were small, the results were not aligned. However, the ORR, PFS, and OS results all suggest better outcomes among patients with CTC levels at baseline that were reduced or eliminated in subsequent cycles compared with CTC levels that persisted postbaseline. Therefore, within the limits of the system used in this study, the data suggest that the response of CTCs to treatment, rather than the presence or absence of CTCs per se, may predict outcomes.

We reported a decrease from baseline CTC levels with doublet chemotherapy in \>28% of patients; in particular, CTC clearance from baseline was noted in 60% of patients in the *nab*-P/C arm. A previous meta-analysis using CELLSEARCH CTC enumeration, which included 6 studies and \>800 patients with MBC showed that ≥5 CTCs/7.5 mL at baseline and persistently elevated levels during treatment were associated with the worst PFS and OS outcomes, irrespective of type and line of treatment.[@CIT0013] In a larger, pooled analysis of \>1900 patients with MBC, the ≥5-CTC threshold at baseline and increased CTC levels after baseline were significantly correlated with decreased PFS and OS compared with baseline levels of \<5 CTCs.[@CIT0007] Similar findings emerged from the large, prospective, randomized study SWOG S0500 (also based on the CELLSEARCH platform), in which patients with TNBC and low CTC levels at baseline, as well as those who had CTC clearance with chemotherapy treatment, had a longer OS compared with those who had elevated CTC levels at baseline and after treatment.[@CIT0010] In addition, treatment with chemotherapy reduced baseline CTC levels in 55% of patients with TNBC. However, changing to an alternative chemotherapy regimen based on CTC levels did not improve survival outcomes in the patients with MBC evaluated in the SWOG S0500 study.

The publication of CTC studies with conflicting results regarding treatment outcomes is acknowledged. For example, a meta-analysis of 50 studies and \>6700 patients demonstrated that systemic therapy, whether single-agent or combination treatment in the neoadjuvant, adjuvant, or metastatic setting, reduced CTC levels in patients with breast cancer overall,[@CIT0014] but the CTC reduction appeared to be limited to patients with HER2+/− disease. However, in addition to including several different CTC platforms, the biology of the breast cancers included in this meta-analysis varied and included multiple disease settings (eg, early stage vs advanced) and subtypes (eg, only 2 TNBC studies \[of which only 1 was in the metastatic setting\]). In addition, a prospective study in TNBC comparing CELLSEARCH and immunomagnetic enrichment/flow cytometry methods revealed an association between baseline CTC levels and OS but not time to progression, and changes in CTC levels during chemotherapy were significantly associated with both time to progression and OS, regardless of the enumeration platform.[@CIT0015]

The present study has potential limitations that must be considered. First, the CELLSEARCH platform relies on the capture of CTCs based on epithelial cell adhesion molecule (EpCAM) expression and excludes populations of low- or non-EpCAM-expressing cells in circulation. As a result, if tumor cells have undergone epithelial to mesenchymal transition, CTC detection may be less precise, as CTCs in TNBC often lack EpCAM expression and exhibit more stem cell-like properties.[@CIT0001],[@CIT0016] In addition, it is possible that the proportion of epithelial cells relative to cells that underwent an epithelial to mesenchymal transition changed during treatment. Therefore, the perceived clearance may be the result of a population of CTCs that became undetectable.[@CIT0017],[@CIT0018] Second, we acknowledge that the small number of CTC patient samples (N = 126) limits the ability to draw definitive conclusions, as this study was not powered to assess the outcomes investigated within. Additional studies including more patient samples are warranted.
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[^1]: **Abbreviation:** ECOG PS, Eastern Cooperative Oncology Group performance status.

[^2]: **Abbreviation:** CTC, circulating tumor cell.

[^3]: **Abbreviations:** C, carboplatin; CTC, circulating tumor cell; G, gemcitabine; *nab*-P, *nab*-paclitaxel; NE, not evaluable; PFS, progression-free survival.
